Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA might support "user fees" for OTC monograph activities -- association's Cope.

This article was originally published in The Tan Sheet

Executive Summary

NDMA WILLING TO CONSIDER "USER FEES" FOR MONOGRAPH ACTIVITIES once again, association President James Cope stressed during discussions with FDAers at the Nonprescription Drug Manufacturers Association annual Research & Scientific Development Conference Nov. 12-13 in Washington, D.C. As part of a dialogue about inadequate appropriated funds for OTC ingredient monograph-related activities, Cope "renew[ed] the pledge" made during 1991 Prescription Drug User Fee Act (PDUFA) negotiations that the trade association would be "willing to discuss" user fees to support OTC drug monograph activities.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel